Cancer Research Communications

Scope & Guideline

Innovating cancer treatment through shared insights.

Introduction

Welcome to the Cancer Research Communications information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Cancer Research Communications, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN-
PublisherAMER ASSOC CANCER RESEARCH
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationCANCER RES COMMUN / Cancer Res. Commun.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404

Aims and Scopes

Cancer Research Communications aims to advance knowledge in the field of oncology through cutting-edge research and clinical studies. The journal encompasses a wide array of topics related to cancer biology, therapy, and patient outcomes, focusing on innovative approaches and methodologies.
  1. Cancer Therapeutics and Targeted Treatments:
    The journal regularly publishes studies on novel therapeutic agents, including targeted therapies, immunotherapies, and combination treatments. This includes exploration of drug mechanisms, resistance, and patient stratification based on genetic and molecular profiles.
  2. Cancer Biology and Mechanisms of Tumorigenesis:
    Research articles delve into the fundamental biological processes underlying cancer development and progression. This includes studies on genetic mutations, signaling pathways, and tumor microenvironment interactions that contribute to malignancy.
  3. Clinical Trials and Translational Research:
    A significant focus is placed on clinical studies, including phase I-III trials, that evaluate the safety and efficacy of new cancer treatments. This also includes studies on biomarkers and patient outcomes to inform clinical decision-making.
  4. Molecular and Cellular Oncology:
    The journal features research on cellular mechanisms, including the role of cancer stem cells, immune evasion, and the tumor microenvironment, emphasizing the molecular pathways that contribute to cancer progression.
  5. Cancer Epidemiology and Health Disparities:
    Research addressing disparities in cancer incidence, treatment outcomes, and access to care for various populations is a consistent theme. This includes studies that investigate the impact of socioeconomic factors on cancer risk and treatment.
Recent publications in Cancer Research Communications highlight several trending and emerging themes that demonstrate the journal's responsiveness to the evolving landscape of cancer research. These themes indicate where the field is heading and the innovative approaches being taken.
  1. Immunotherapy and Immune Microenvironment Studies:
    There is a significant increase in research focused on immunotherapy, including CAR T-cell therapies and immune checkpoint inhibitors. Studies exploring the immune microenvironment and its role in therapy response are gaining prominence, reflecting the growing importance of immuno-oncology.
  2. Precision Medicine and Biomarker Research:
    Publications increasingly emphasize the role of precision medicine, with a focus on identifying biomarkers for patient stratification and treatment efficacy. This trend aligns with the need for personalized treatment approaches tailored to individual patient profiles.
  3. Multi-Omics Approaches:
    Emerging research utilizing multi-omics strategies, such as genomics, proteomics, and metabolomics, is becoming more prevalent. These approaches aim to provide a comprehensive understanding of cancer biology and treatment responses.
  4. Targeting the Tumor Microenvironment:
    Studies investigating the tumor microenvironment's role in cancer progression and therapy resistance are on the rise. This includes research on stromal interactions, immune cell infiltration, and metabolic reprogramming within tumors.
  5. Health Disparities and Cancer Epidemiology:
    There is a growing focus on understanding health disparities in cancer outcomes, with research highlighting the influence of socioeconomic, racial, and geographic factors on cancer incidence and treatment access. This trend reflects a broader commitment to addressing inequities in cancer care.

Declining or Waning

While Cancer Research Communications continues to explore a vast array of cancer-related topics, certain themes appear to be declining in frequency or prominence. These waning scopes may reflect shifts in research focus or emerging priorities in the field.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in studies focused solely on traditional chemotherapy regimens, as research increasingly shifts towards personalized medicine and targeted therapies that offer improved specificity and reduced toxicity.
  2. Basic Laboratory Techniques without Clinical Relevance:
    Research papers that focus exclusively on basic laboratory techniques or models, without a clear translational application or clinical relevance, appear to be less frequently published, as the journal emphasizes studies with direct implications for patient care.
  3. Single-Factor Studies:
    There is a waning interest in studies that investigate single factors in isolation, such as individual genetic mutations or isolated biochemical pathways, as the field moves towards integrative approaches that consider the multifactorial nature of cancer.
  4. General Cancer Awareness Campaigns:
    Papers focused on general cancer awareness and education initiatives without substantial data or research backing are becoming less prevalent, reflecting a trend towards more evidence-based, impactful research.

Similar Journals

Advances in Cancer Biology-Metastasis

Innovating Insights into Cancer Metastasis.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

Cancer Communications

Connecting Researchers, Practitioners, and Patients in Oncology
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

CANCER SCIENCE

Exploring the forefront of cancer science and medicine.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

CANCER INVESTIGATION

Driving innovation in cancer studies for impactful discoveries.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Cancer Cell International

Unveiling Innovations in Cancer Biology
Publisher: BMCISSN: Frequency: 1 issue/year

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Fostering Breakthroughs in Cancer Treatment Strategies
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

NATURE REVIEWS CANCER

Pioneering Knowledge in Cancer Prevention and Treatment
Publisher: NATURE PORTFOLIOISSN: 1474-175XFrequency: 12 issues/year

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.

Annual Review of Cancer Biology

Exploring the Complexities of Cancer Science
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

CANCER RESEARCH

Exploring the depths of cancer prevention and diagnosis.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Unlocking the secrets of cancer biology and therapy.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.